chufangao/CTO huggingface dataset:
Clinical trial NCT03903640: Optune Device - TT Field Plus Nivolumab and Ipilimumab for Melanoma With Brain Metastasis
Official title: Phase II Study of Optune Device - TT Field Plus Nivolumab and Ipilimumab for Melanoma With Brain Metastasis
Sponsor: Washington University School of Medicine (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The study was terminated early on 03/09/2022 due to low accrual during the COVID-19 pandemic.
Enrollment: 2.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-10-14
Primary completion date: 2020-06-08
Completion date: 2021-11-03
Limitations and caveats: The study was opened to enrollment from 07/01/2019 through 03/09/2022. The study was terminated early due to low enrollment. The low enrollment was due to the COVID-19 pandemic and no external referrals for the trial. The Principal Investigator reached out to other academic institutions about opening the trial but there was not any interest.
Plan to share individual participant data: NO
Clinical trial NCT04330300: Coronavirus (COVID-19) ACEi/ARB Investigation
Official title: The CORONAvirus Disease 2019 Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker InvestigatiON (CORONACION) Randomized Clinical Trial
Acronym: CORONACION
Sponsor: National University of Ireland, Galway, Ireland (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: SUSPENDED 
Why stopped: Challenges with funding and very low incidence of COVID-19 at Irish study site
Enrollment: 2414.0 (ESTIMATED)
Number of arms: 2.0
Start date: 2020-04-30
Primary completion date: 2021-07-31
Completion date: 2021-12-01
Plan to share individual participant data: YES
IPD time frame: 12-24 months
IPD access criteria: To be determined
Clinical trial NCT04351191: PRophylaxis of Exposed COVID-19 Individuals With Mild Symptoms Using choloroquinE Compounds
Official title: Use and Dosage of Hydroxychloroquine and Chloroquine to Convert Symptomatic RT-PCR Positive Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Coronavirus Infectious Disease 2019 (COVID-19) Patients to RT- PCR-Negative as a Means to Reduce Hospitalization Rate
Acronym: PRECISE
Sponsor: Government of Punjab, Specialized Healthcare and Medical Education Department (OTHER_GOV)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Poor accrual
Enrollment: 137.0 (ACTUAL)
Number of arms: 4.0
Start date: 2020-04-15
Primary completion date: 2020-08-23
Completion date: 2020-08-30
Plan to share individual participant data: NO
Clinical trial NCT02945280: Apixaban for Routine Management of Upper Extremity Deep Venous Thrombosis
Official title: Apixaban for Routine Management of Upper Extremity Deep Venous Thrombosis
Acronym: ARM-DVT
Sponsor: Intermountain Health Care, Inc. (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: COVID-19 resource allocation
Enrollment: 52.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-02-22
Primary completion date: 2021-11-11
Completion date: 2021-11-11
Plan to share individual participant data: NO
Clinical trial NCT04602390: Assessment of ANK-700 in Patients With Relapsing Remitting Multiple Sclerosis
Official title: A Phase 1 Study of the Safety and Tolerability of Single and Multiple Doses of ANK-700 in Patients With Relapsing Remitting Multiple Sclerosis
Acronym: MoveS-it
Sponsor: Anokion SA (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 33.0 (ACTUAL)
Number of arms: 5.0
Start date: 2020-11-06
Primary completion date: 2024-04-23
Completion date: 2024-04-23
Plan to share individual participant data: NO
Clinical trial NCT04262869: Platinum-Based Chemotherapy and Durvalumab for the Treatment of Stage IIIB or IV Non-small Cell Lung Cancer
Official title: Phase 2 Study of Platinum-Based Chemotherapy in Combination With Durvalumab (MEDI 4736) for NSCLC in Patients With a Poor Performance Status and the Elderly
Sponsor: Emory University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Due to accrual issues
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-03-27
Primary completion date: 2021-10-18
Completion date: 2021-10-18
Plan to share individual participant data: NO
IPD sharing description: Results of the trial and not individual patient data will be shared. The study protocol, consent, and investigator's brochure will be available. The statistical plan is incorporated into the protocol, along with inclusion and exclusion criteria.
Clinical trial NCT02939365: Precision Medicine Offers Belatacept Monotherapy
Official title: Precision Medicine Offers Belatacept Monotherapy (PROBE)
Acronym: PROBE
Sponsor: University of California, San Francisco (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Because of inability to get FDA approval for
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-02-28
Primary completion date: 2020-02-29
Completion date: 2022-12-31
Plan to share individual participant data: NO
Clinical trial NCT03720483: Inhaled NAC in Treatment of IPF
Official title: Pilot Study to Evaluate Inhaled N-Acetylcysteine in Pulmonary Fibrosis
Sponsor: University of Colorado, Denver (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: The study encountered challenges during startup due to the COVID-19 epidemic and was withdrawn.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-01-31
Primary completion date: 2023-12-31
Completion date: 2023-12-31
Plan to share individual participant data: NO
Clinical trial NCT03770000: Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma
Official title: An Open Label, Phase I/II Study to Evaluate the Safety and Efficacy of Tenalisib (RP6530), a Novel PI3K δ/γ Dual Inhibitor Given in Combination With a Histone Deacetylase (HDAC) Inhibitor, Romidepsin in Adult Patients With Relapsed/Refractory T-cell Lymphoma
Sponsor: Rhizen Pharmaceuticals SA (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 33.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-03-12
Primary completion date: 2021-05-14
Completion date: 2021-05-14
Plan to share individual participant data: NO
Clinical trial NCT03883581: Impact of Nuedexta on Bulbar Physiology and Function in ALS
Official title: Impact of Nuedexta on Bulbar Physiology and Function in ALS
Sponsor: University of Florida (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 28.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-07-25
Primary completion date: 2021-09-13
Completion date: 2021-11-22
Plan to share individual participant data: NO
Clinical trial NCT03689582: Radiolabeled Gallium-68 (68Ga-PSMA) for PET/CT Imaging to Detect Prostate Cancer
Official title: 68GA-PSMA Fusion PET/MRI For Image-Guided Prostate Biopsies
Sponsor: University of Michigan Rogel Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: due to pandemic related constraints
Enrollment: 11.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-11-13
Primary completion date: 2020-02-27
Completion date: 2020-02-27
Limitations and caveats: Early termination leading to small numbers of subjects analyzed.
Plan to share individual participant data: YES
IPD sharing description: Codified data will be archived and stored in an imaging repository with limited metadata for analysis. Individuals seeking use of these data should contact the study chair. A data sharing contract for a HIPAA limited dataset will need to be executed prior to data sharing.
IPD time frame: Available as requested. Data will be archived indefinitely for research purposes.
IPD access criteria: Individuals seeking use of these data should contact the study chair.
Clinical trial NCT03237611: Low Dose Aprepitant for Patients Receiving Carboplatin
Official title: Phase II Trial Testing the Antiemetic Efficacy of a Single-day Low Dose Aprepitant (or Fosaprepitant) Added to a 5-HT3 Receptor Antagonist Plus Dexamethasone in Patients Receiving Carboplatin
Sponsor: Albert Einstein College of Medicine (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Expired IRB approval on 2/11/21
Enrollment: 15.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-10-30
Primary completion date: 2021-02-11
Completion date: 2021-02-11
Baseline population: For purposes of this single arm study, the determination of whether fosaprepitant or aprepitant was administered was entirely the choice of the ordering oncologist. Both agents are NK-1 receptor antagonists. Fosaprepitant is a phosphorylated analog of aprepitant and rapidly converts to aprepitant following IV injection.
Plan to share individual participant data: NO
Clinical trial NCT02308111: Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis
Official title: A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Patients With Primary Biliary Cholangitis
Acronym: COBALT
Sponsor: Intercept Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: The DMC made the recommendation to not pursue further enrollment given the lack of feasibility for this post-marketing study as designed.
Enrollment: 334.0 (ACTUAL)
Number of arms: 2.0
Start date: 2014-12-26
Primary completion date: 2021-12-23
Completion date: 2021-12-23
Baseline population: All randomized participants who received at least 1 dose of the study drug.
Limitations and caveats: The estimated effect of treatment from the ITT population was underpowered and potentially biased, resulting in difficulties in the interpretation of the tests of hypotheses for the primary and key secondary endpoints.
Clinical trial NCT02528708: A Program to Evaluate Riastap® and FIBTEM® for the Early Control and Treatment of Postpartum Hemorrhage (PERFECT PPH)
Official title: A Program to Evaluate Riastap® and FIBTEM® for the Early Control and Treatment of Postpartum Hemorrhage (PERFECT PPH)
Acronym: PERFECT PPH
Sponsor: Yale University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: The study never began.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-01-31
Primary completion date: 2021-12-31
Completion date: 2021-12-31
Clinical trial NCT04898023: Zinc and Green Tea Extract for Community Respiratory Viral Infections
Official title: Evaluation of Combination Zinc and Green Tea Extract Supplementation on Reduction in Symptom Duration and Severity Associated With Community Respiratory Viral Infections: a Randomized Control Trial (ZiPhenol Study)
Sponsor: University of Missouri-Columbia (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Loss of funding
Enrollment: 17.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-09-21
Primary completion date: 2023-10-31
Completion date: 2023-12-20
Clinical trial NCT02841540: A Study of H3B-8800 (RVT-2001) in Participants With Lower Risk Myelodysplastic Syndromes
Official title: An Open-label, Multicenter Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia
Acronym: Encore-MDS
Sponsor: Hemavant Sciences GmbH (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: The study was terminated after conducting an interim analysis of the available data where it became evident that the observed efficacy results were not in alignment with the initially set expectations.
Enrollment: 127.0 (ACTUAL)
Number of arms: 3.0
Start date: 2016-10-06
Primary completion date: 2024-02-13
Completion date: 2024-02-13
Clinical trial NCT05125679: Effect of Guselkumab on Cardiovascular Risk Surrogate Markers in Participants With Moderate to Severe Plaque Psoriasis
Official title: A Phase 4, Interventional, Single-arm, Open-label Study Evaluating the Effect of Guselkumab on Cardiovascular Risk Surrogate Markers in Participants With Moderate to Severe Plaque Psoriasis
Acronym: G-CARE
Sponsor: Janssen-Cilag Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Terminated (A strategic decision was made not to further execute the study. This decision was not based on a safety concern)
Enrollment: 15.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-11-23
Primary completion date: 2023-07-28
Completion date: 2023-07-28
Plan to share individual participant data: YES
IPD sharing description: The data sharing policy of the Janssen Pharmaceutical Companies of Johnson and Johnson is available at www.janssen.com/clinical- trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) project site at yoda.yale.edu
Clinical trial NCT02763579: A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)
Official title: A Phase I/III, Randomized, Double-Blind, Placebo-Controlled Study of Carboplatin Plus Etoposide With or Without Atezolizumab (Anti-PD-L1 Antibody) in Patients With Untreated Extensive-Stage Small Cell Lung Cancer
Acronym: IMpower133
Sponsor: Hoffmann-La Roche (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 503.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-06-07
Primary completion date: 2018-04-24
Completion date: 2022-07-07
Baseline population: The intent-to-treat (ITT) population included 503 participants (All) with 403 in the Global population. An additional 100 participants enrolled in the China Extension. The China population included 10 Chinese participants from the Global population plus 100 participants from the China Extension. Separate analyses were performed for the Global population and the China population in the study.
Clinical trial NCT04583488: Intraperitoneal Docetaxel in Combination With mFOLFOX6 for Gastric Cancer Patients With Peritoneal Carcinomatosis
Official title: A Phase I Study of Intraperitoneal Docetaxel in Combination With 5-Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) for Gastric Cancer Patients With Peritoneal Carcinomatosis
Sponsor: Johns Hopkins University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: PI left institution
Enrollment: 2.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-11-01
Primary completion date: 2024-08-06
Completion date: 2024-08-06
Plan to share individual participant data: NO
Clinical trial NCT02394535: Nab-Paclitaxel, Capecitabine, and Radiation Therapy Following Induction Chemotherapy in Treating Patients With Locally Advanced Pancreatic Cancer
Official title: Combining Abraxane With Capecitabine and Radiation Therapy for Consolidation of Treatment Following Induction Chemotherapy for Locally Advanced Pancreatic Cancer
Sponsor: M.D. Anderson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 25.0 (ACTUAL)
Number of arms: 1.0
Start date: 2015-11-12
Primary completion date: 2022-08-31
Completion date: 2022-08-31
Clinical trial NCT04607603: Efficacy of Cannabidiol in Knee Osteoarthritis
Official title: Efficacy of Cannabidiol in Treatment of Pain Due to Symptomatic Osteoarthritis of the Knee: A Randomized, Double-blind, Placebo-controlled Clinical Trial
Sponsor: Medical University of Vienna (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 86.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-10-13
Primary completion date: 2022-02-17
Completion date: 2022-03-29
Clinical trial NCT03137082: Guanfacine to Reduce Relapse Risk in Women With Alcohol Use Disorder (AUD)
Official title: Guanfacine to Reduce Relapse Risk in Women With Alcohol Use Disorder (AUD)
Sponsor: Stony Brook University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 32.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-07-12
Primary completion date: 2021-03-31
Completion date: 2021-03-31
Baseline population: 32 women were enrolled in the study. N=17 were not eligible, N=15 were randomized to study medication
Limitations and caveats: Delay in study commencement and staff losses leading to small sample size.
Plan to share individual participant data: NO
Clinical trial NCT05019677: GP Chemotherapy in Combination With Tislelizumab and Ociperlimab as First-line Treatment in Advanced BTC
Official title: A Study to Evaluate GP Chemotherapy in Combination With Tislelizumab(Anti-PD-1) and Ociperlimab(Anti-TIGIT) as First-line Treatment in Participants With Unresectable Advanced BTC
Sponsor: Fudan University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Repeat registration
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-09-01
Primary completion date: 2024-12-01
Completion date: 2024-12-01
Plan to share individual participant data: NO
Clinical trial NCT04149899: Safety and IOP-Lowering Effects of WB007
Official title: A Phase 1/2a Assessment of WB007 Ophthalmic Solution in Subjects With Primary Open-Angle Glaucoma or Ocular Hypertension
Sponsor: Whitecap Biosciences, LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 77.0 (ACTUAL)
Number of arms: 6.0
Start date: 2019-11-14
Primary completion date: 2021-01-31
Completion date: 2022-12-14
Plan to share individual participant data: NO
Clinical trial NCT03100253: Rheumatoid Arthritis Treatment After First Anti-TNF INvestiGation
Official title: Open-label, Randomized Controlled Trial Comparing Tocilizumab to Anti-TNF Treatment and Discovery of Biomarkers for Treatment Selection in Rheumatoid Arthritis Patients With Inadequate Response to a First Anti-TNF
Acronym: RAFTING
Sponsor: Mario Negri Institute for Pharmacological Research (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Slow recrutiment
Enrollment: 208.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-03-01
Primary completion date: 2021-12-01
Completion date: 2021-12-31
Plan to share individual participant data: UNDECIDED
Clinical trial NCT02557672: PCC vs. FFP for Post Cardiopulmonary Bypass Coagulopathy and Bleeding
Official title: Prothrombin Complex Concentrate (PCC) Compared to Fresh Frozen Plasma (FFP) for Post-cardiopulmonary Bypass Coagulopathy and Bleeding, a Prospective Randomized Trial at Large US Medical Center.
Sponsor: Mayo Clinic (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 106.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-08-31
Primary completion date: 2021-06-30
Completion date: 2022-01-31
Plan to share individual participant data: NO
Clinical trial NCT04678453: Safety of SNK01 in Subjects With Alzheimer's Disease (ASK-AD)
Official title: Single Center, Open Label, Phase 1 Study to Evaluate the Safety, Tolerability and Exploratory Efficacy of SNK01 in Subjects With Alzheimer's Disease (AD)
Acronym: ASK-AD
Sponsor: NKGen Biotech, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: The study was terminated after completing the dose escalation portion of the study. The expansion cohort was not initiated to conduct a global trial based on the approved US IND using a new manufacturing process.
Enrollment: 10.0 (ACTUAL)
Number of arms: 4.0
Start date: 2021-01-06
Primary completion date: 2023-08-16
Completion date: 2024-01-31
Clinical trial NCT03605667: Study of BHV-4157 in Alzheimer's Disease
Official title: A Phase 2 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of BHV-4157 in Patients With Mild to Moderate Alzheimer's Disease
Acronym: T2 Protect AD
Sponsor: Biohaven Pharmaceuticals, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 350.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-07-31
Primary completion date: 2020-12-15
Completion date: 2021-12-23
Baseline population: Treated population included enrolled and randomized participants who received at least 1 dose of blinded study therapy (troriluzole or placebo).
Limitations and caveats: All participants in the OLE phase underwent a termination visit 2 weeks after the last dose of troriluzole.
Clinical trial NCT03822962: Pain Management Following Sinus Surgery
Official title: Post-operative Pain Management Following Functional Endoscopic Sinus Surgery
Sponsor: University of Nebraska (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: TERMINATED 
Why stopped: Decrease in accrual during the COVID-19 pandemic and several sites withdrawing
Enrollment: 10.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-11-07
Primary completion date: 2023-05-30
Completion date: 2023-05-30
Plan to share individual participant data: NO
Clinical trial NCT03472833: High-dose Vitamin D3 in Pancreas Cancer
Official title: Influence of High Dose Vitamin D3 Intake on Outcome in Pancreatic Cancer Surgery: Prospective, Randomized, Open, Controlled Pilot Study
Acronym: VITdCUT
Sponsor: Medical University of Graz (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: slow recruitment, patients lost to follow-up due to Covid-19 pandemic.
Enrollment: 25.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-04-01
Primary completion date: 2021-04-20
Completion date: 2021-04-20
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04170959: The Addition of Metformin to Definitive Radiotherapy in Patients With Stage III NSCLC
Official title: Randomized Phase II Trial of Definitive Radiotherapy With or Without metFORMin in Patients With Inoperable Stage III Non-small Cell Lung Cancer
Acronym: RADFORMIN
Sponsor: University Hospital, Antwerp (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Loss of external funding
Enrollment: 3.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-07-30
Primary completion date: 2021-01-08
Completion date: 2021-01-08
Clinical trial NCT03712228: A Study to Investigate CSL312 in Subjects With Hereditary Angioedema (HAE)
Official title: A Multicenter, Randomized, Placebo-controlled, Parallel-arm Study to Investigate the Efficacy, Pharmacokinetics, and Safety of CSL312 in Subjects With Hereditary Angioedema
Sponsor: CSL Behring (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 44.0 (ACTUAL)
Number of arms: 5.0
Start date: 2018-10-29
Primary completion date: 2021-10-15
Completion date: 2021-10-15
Baseline population: The Intent-to-Treat (ITT) population consisted of all subjects who provided informed consent, underwent any study screening procedure, and who were assigned to treatment in Treatment Period 1 or to treatment in Treatment Period 2, regardless of whether they received investigational product.
Plan to share individual participant data: NO
Clinical trial NCT03008460: Efficacy, Safety and Tolerability of Eziclen®/Izinova® Versus Klean-prep® on Bowel Cleansing in Adolescents Undergoing Colonoscopy
Official title: Efficacy, Safety and Tolerability of a Bowel Cleansing Preparation (Eziclen/Izinova®) in Paediatric Subjects Undergoing Colonoscopy: a Phase III, Multicentre, Randomised, Comparative Study Versus Klean-Prep® (PEG-Electrolytes), Administered on the Day Before Colonoscopy, Investigator-blinded, Non-inferiority in Adolescents of 12 to 17 Years of Age (Inclusive) >40 kg
Acronym: EASYKID
Sponsor: Ipsen (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 250.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-10-15
Primary completion date: 2020-02-24
Completion date: 2020-06-29
Baseline population: The intention-to-treat (ITT) population included all randomised subjects who received even a partial dose of study drug.